天演药业上涨2.82%，报2.241美元/股，总市值1.06亿美元

Core Insights - Tianyan Pharmaceutical (ADAG) experienced a stock price increase of 2.82%, reaching $2.241 per share with a total market capitalization of $106 million as of August 8 [1] - The company's financial data indicates a total revenue of $103,200 as of December 31, 2024, representing a year-over-year decrease of 99.43%, while the net profit attributable to shareholders was -$33.4241 million, a decline of 76.41% year-over-year [1] Company Overview - Tianyan Pharmaceutical is a platform-driven biopharmaceutical company focused on the development of clinical products, particularly in the field of cancer immunotherapy based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to provide solutions for cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]